Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction With the Drug-eluting Resorbable Magnesium Scaffold: the BEST- MAG Multicentre Study. (BElgian ST-segment Elevation Myocardial Infarction Treatment With Resorbable MAGnesium Scaffold).
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- A device oriented composite endpoint (DOCE) including cardiac death, target vessel myocardial infarction (attributable to the culprit lesion) and ischemic-driven target lesion revascularization (TLR) within 12 months after the index procedure.
研究概览
简要总结
Percutaneous treatment of coronary artery disease depends on the implantation of stents within diseased coronary segments. Compared with conventional bare-metal and drug- eluting stents, which remain permanently within the coronary anatomy, bioresorbable scaffolds (BRS) offer several potential advantages due to its resorbable properties. The resorbable magnesium scaffold Magmaris has demonstrated favourable outcomes in patients with stable coronary artery disease. In particular, in comparison to polymeric bioresorbable scaffolds, no cases of stent thrombosis have been reported in over two years of follow-up suggesting that magnesium-based resorbable scaffolds have low thrombogenicity and might be particularly beneficial for patients presenting with ST- segment myocardial infarction. A recent pilot study in eighteen patients supports this concept, which has led to the development of the proposed prospective multicentre study including intra-coronary imaging with long-term clinical follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients presenting with a ST-elevation myocardial infarction (STEMI) with symptoms onset <24 hours or with ongoing symptoms.
- •Signed patient informed consent.
排除标准
- •Age < 18 or > 70 years.
- •Pregnancy or breastfeeding.
- •Cardiogenic shock.
- •Creatinine clearance ≤30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated GFR) and not on dialysis. Note: chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance.
- •Infarct-artery reference diameter < 2.7 or > 4.0 mm (within the segment of the culprit lesion) by visual estimation, and OCT infarct-artery distal reference mean lumen diameter < 2.7 or > 3.7 mm
- •Non-optimal vessel preparation after predilatation: residual stenosis >30%.
- •Culprit lesion length > 21 mm.
- •Culprit lesion located within a previously stented segment (stent thrombosis or in-stent restenosis).
- •Culprit lesion involving a saphenous vein graft.
- •Culprit lesion involving a bifurcation with an intended two-stent implantation strategy.
- •Ostial right coronary artery
- •Severe calcification or tortuosity of the infarct-related artery.
- •Absolute contraindication to a 12 months dual antiplatelet therapy.
- •Life expectancy < 3 years.
- •Patients taking oral anticoagulant therapy
结局指标
主要结局
A device oriented composite endpoint (DOCE) including cardiac death, target vessel myocardial infarction (attributable to the culprit lesion) and ischemic-driven target lesion revascularization (TLR) within 12 months after the index procedure.
时间窗: 1 year
DOCE at 12 months
次要结局
- Procedural success defined as the delivery and deployment of RMS at the intended target lesion with a final residual stenosis ≤20% by visual estimation.(in-hospital)
- All-cause death, cardiac death, non-TVR, any revascularization at 1, 6, 12 and 24 months.(2 years)
- Definite or probable scaffold thrombosis.(2 years)
- DOCE at 1-,6- and 24-months follow-up periods.(2 years)
- Vessel healing assessment through an angiographic with OCT follow- up procedure at 15 months in predetermined participating centres(15 months)